Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

I-gel vs LMA Supreme in Laparoscopic Gynecological Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02923427
Recruitment Status : Completed
First Posted : October 4, 2016
Results First Posted : October 8, 2020
Last Update Posted : October 27, 2020
Sponsor:
Information provided by (Responsible Party):
Sule Ozbilgin, Dokuz Eylul University

Brief Summary:
To compare the effects of i-gel and Laryngeal mask airway Supreme (LMA-Supreme) on ventilation parameters and surgical view during Trendelenburg Position laparoscopic gynecological surgery in cases administered positive pressure ventilation without the use of neuromuscular agents.

Condition or disease Intervention/treatment Phase
Airway Morbidity Anaesthesia Device: Laryngeal mask Supreme Evaluation Device: i-gel Evaluation Not Applicable

Detailed Description:

Prospective, randomized and double-blind study, aged from 18 to 65 years undergoing elective laparoscopic gynecological surgery.

The patients are randomly assigned to 2 groups:

  • Group 1: i-gel
  • Group 2: LMA- Supreme

Procedure:

The investigation protocol contains the following sections:

  1. Induction of anaesthesia. For preoperative sedation 0.02 mg/kg midazolam IV will be administered. 2 minutes of 0.2 µ/kg/min remifentanil and 6 mg kg st-1 propofol infusion, IV 1-2 mg kg-1 propofol . No muscle relaxant will be used for insertion of the airway device.
  2. Bispectral index values will be held between 40-60.Bispectral index values will be within this interval by increasing or decreasing propofol infusion by 1 mg/kg after additional bolus dose of propofol (1 mg/kg).
  3. Insertion of the airway device. The size of the airway device used is based on the manufacturers' recommendations. All devices are deflated a lubricated prior to use. Once inserted, the cuff is be inflated with a manometer up to 60 cm H20 Data recorded: size of airway device, time an number of attempts.
  4. Anesthesia maintenance will be ensured by 50% O2/air with 0.1-0.4 µ kg/min-1 remifentanil and 50-150 µ kg/ min-1 (4-10 mg/kg/hr) propofol IV infusion
  5. Functionality of the gastric drainage channel of the airway device: passage of a 14 G size tube.
  6. Measurement of airway seal pressure (oropharyngeal leak pressure (OLP): at baseline, and at 2 minutes after airway device insertion (T1), 10 minutes after insufflation (T2), before desufflation (T3), before removal of airway device (T4). The maximum pressure allowed is 40 cm H2O.
  7. Ventilatory mechanics and parameters and hemodynamic parameters are measured at baseline, and at T1, T2, T3 and T4.
  8. Perioperative complications: Cough, vomiting, laryngeal spasm, laryngeal Stridor, airway intervention requirements, hypoxia (SpO2 < 92%)
  9. Removal of the airway device: Presence of blood - 3 level grading (1:no blood; 2: trace amounts of blood; 3: clear amounts of blood). Complications: sore throat ( VAS:10-point scale), dysphonia (yes/no), dysphagia (yes/no).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 112 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Comparison of I-gel and LMA Supreme Without Neuromuscular Blocker in Laparoscopic Gynecological Surgery
Actual Study Start Date : November 2015
Actual Primary Completion Date : September 2017
Actual Study Completion Date : November 2017

Arm Intervention/treatment
Active Comparator: Laryngeal mask Supreme
Insertion of the "Laryngeal mask Supreme" and evaluation of its clinical performance
Device: Laryngeal mask Supreme Evaluation
Evaluation of clinical performance in terms of Insertion, ventilation and complications

Experimental: i-gel
Insertion of the "i-gel" and evaluation of its clinical performance
Device: i-gel Evaluation
Evaluation of clinical performance in terms of Insertion,ventilation and complications




Primary Outcome Measures :
  1. Airway Seal Pressure Values [ Time Frame: At baseline and at 15, 30 and 60 minutes ]
    This value is important as it indicates the feasibility of positive pressure ventilation and the degree of airway protection from supracuff soiling. It is also used in LMA studies as an index of successful placement.Airway pressures of ≈20 cm H2O are typically required in routine practice.


Secondary Outcome Measures :
  1. Visual Quality [ Time Frame: during pneumoperitoneum ]
    quality of surgical view will evaluate by the scala. quality of surgical view will be assessed with points from 1 to 4 by the surgeon blind to the airway device; (1:best, 4: worst).

  2. Gastric Tube Insertion [ Time Frame: following airway device insertion up to 5 minutes ]
    Number of Participants According to Ease of Gastric Tube Insertion.Ease of passage of a gastric tube as: very easy, easy, difficult or very difficult.

  3. Postoperative Pharyngolaryngeal Morbidity [ Time Frame: postoperative first hour and 24th hour ]
    Sore throat evaluted by Visual Analogue Scale. The visual analog scale, also known as the graphic rating scale is a simple, valid and reliable subjective measure. Scores are ranked on a 10-cm line that stretches between two extremes - "no pain" and "worst pain". Total range provided"0 (no pain) to 10 (worst pain).

  4. Sufficiency of Pneumoperitoneum [ Time Frame: baseline ]
    Number of Participants with Sufficiency of Pneumoperitoneum. Sufficiency of pneumoperitoneum for the surgical procedure according to surgeon, described as sufficient or insufficient questionaire.

  5. Mean Airway Pressure Values [ Time Frame: At baseline and at 15, 30 and 60 minutes ]
    Mean airway pressure typically refers to the mean pressure applied during positive-pressure mechanical ventilation. Mean airway pressure correlates with alveolar ventilation, arterial oxygenation, hemodynamic performance, and barotrauma.

  6. Dysphonia With Yes/no. [ Time Frame: postoperative first hour and 24th hour ]
    We evaluated while a patient was talking with us that the patient has dysphonia or not .

  7. Disphagia [ Time Frame: postoperative first hour and 24th hour ]
    We asked the question that you have a pain while you were swallowing, yes or not.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. American Society of Anesthesiologists classification group I-II
  2. between 18-65 years
  3. undergoing elective laparoscopic gynecological surgery

Exclusion Criteria:

  1. Those with any neck or upper respiratory tract pathology
  2. Those at risk of gastric content regurgitation/aspiration (previous upper Gastrointestinal system surgery, known hiatus hernia, gastroesophageal reflux, history of peptic ulcers, full stomach, pregnancy)
  3. Those with low pulmonary compliance or high airway resistance (chronic pulmonary diseases)
  4. Obese patients (BMI >35)
  5. Those with throat pain, dysphagia and dysphonia
  6. Those with possible or previous difficult airway
  7. Those with operations planned for longer than 4 hours
  8. Conversion to laparatomy
  9. Neuromuscular blocking agent used

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02923427


Locations
Layout table for location information
Turkey
Dokuz Eylül University, School of Medicine, Department of Anesthesiology and Reanimation
İzmir, Turkey, 35340
Sponsors and Collaborators
Dokuz Eylul University
Investigators
Layout table for investigator information
Study Director: Ferim Günenç, MD Dokuz Eylül University, School of Medicine, Department of Anesthesiology and Reanimation
  Study Documents (Full-Text)

Documents provided by Sule Ozbilgin, Dokuz Eylul University:
Layout table for additonal information
Responsible Party: Sule Ozbilgin, Dokuz Eylul University, MD, Anesthesiologists., Dokuz Eylul University
ClinicalTrials.gov Identifier: NCT02923427    
Other Study ID Numbers: 266-SBKAEK
First Posted: October 4, 2016    Key Record Dates
Results First Posted: October 8, 2020
Last Update Posted: October 27, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Keywords provided by Sule Ozbilgin, Dokuz Eylul University:
laryngeal mask Supreme
i-gel
laparoscopic gynecological surgery